These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
513 related articles for article (PubMed ID: 11752075)
1. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075 [TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. Kumar R; Xiu Y; Yu JQ; Takalkar A; El-Haddad G; Potenta S; Kung J; Zhuang H; Alavi A J Nucl Med; 2004 Dec; 45(12):2058-62. PubMed ID: 15585482 [TBL] [Abstract][Full Text] [Related]
3. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. Boland GW; Blake MA; Holalkere NS; Hahn PF AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700 [TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients. Lu Y; Xie D; Huang W; Gong H; Yu J Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976 [TBL] [Abstract][Full Text] [Related]
5. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444 [TBL] [Abstract][Full Text] [Related]
8. (18)F-FDG PET versus (18)F-FDG PET/CT for adrenal gland lesion characterization: a comparison of diagnostic efficacy in lung cancer patients. Sung YM; Lee KS; Kim BT; Choi JY; Chung MJ; Shim YM; Yi CA; Kim TS Korean J Radiol; 2008; 9(1):19-28. PubMed ID: 18253072 [TBL] [Abstract][Full Text] [Related]
9. The value of adding (18)F-FDG PET/CT to adrenal protocol CT for characterizing adrenal metastasis (≥ 10 mm) in oncologic patients. Park SY; Park BK; Kim CK AJR Am J Roentgenol; 2014 Feb; 202(2):W153-60. PubMed ID: 24450697 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience. Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207 [TBL] [Abstract][Full Text] [Related]
11. Clinical Value of 18F-FDG PET/CT in Detecting Adrenal Metastasis in Patients with Hepatocellular Carcinoma. Lin Y; Jeng LB; Wang HY; Tsai SC; Lin WY; Kao CH Technol Cancer Res Treat; 2015 Oct; 14(5):593-9. PubMed ID: 24945368 [TBL] [Abstract][Full Text] [Related]
12. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046 [TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT in the evaluation of adrenal masses. Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184 [TBL] [Abstract][Full Text] [Related]
14. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Brady MJ; Thomas J; Wong TZ; Franklin KM; Ho LM; Paulson EK Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions. Ciftci E; Turgut B; Cakmakcilar A; Erturk SA Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494 [TBL] [Abstract][Full Text] [Related]
16. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. Vikram R; Yeung HD; Macapinlac HA; Iyer RB AJR Am J Roentgenol; 2008 Nov; 191(5):1545-51. PubMed ID: 18941099 [TBL] [Abstract][Full Text] [Related]
17. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. Metser U; Miller E; Lerman H; Even-Sapir E AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662 [TBL] [Abstract][Full Text] [Related]
18. High False Positivity in Positron Emission Tomography is a Potential Diagnostic Pitfall in Patients with Suspected Adrenal Metastasis. Lang BH; Cowling BJ; Li JY; Wong KP; Wan KY World J Surg; 2015 Aug; 39(8):1902-8. PubMed ID: 25809060 [TBL] [Abstract][Full Text] [Related]
19. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]